Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by MGO One Seven LLC

MGO One Seven LLC increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 216.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,813 shares of the company’s stock after purchasing an additional 33,377 shares during the period. MGO One Seven LLC’s holdings in Teva Pharmaceutical Industries were worth $1,076,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in TEVA. Barclays PLC lifted its holdings in shares of Teva Pharmaceutical Industries by 31.7% in the third quarter. Barclays PLC now owns 427,595 shares of the company’s stock valued at $7,705,000 after buying an additional 102,848 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $50,000. Franklin Resources Inc. grew its stake in shares of Teva Pharmaceutical Industries by 141.7% in the 3rd quarter. Franklin Resources Inc. now owns 155,091 shares of the company’s stock worth $2,674,000 after purchasing an additional 90,920 shares during the last quarter. DGS Capital Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after purchasing an additional 872 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Teva Pharmaceutical Industries by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 7,458 shares of the company’s stock valued at $164,000 after purchasing an additional 2,297 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $14.88 on Friday. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The business’s 50-day moving average price is $15.23 and its two-hundred day moving average price is $17.56. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a market capitalization of $16.87 billion, a P/E ratio of -10.26, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. UBS Group dropped their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Bank of America reduced their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 6th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.